Okogen logo

About Us

A clinical-stage antiviral company, working in the eye first

One molecule, four pillars

Okogen is developing ranpirnase, a host-directed ribonuclease with broad-spectrum antiviral activity, as a platform technology across four therapeutic pillars.

The company has freedom to operate and unencumbered access to develop, manufacture and market ranpirnase in the U.S. and globally. Our lead product candidate, Treyegen™ (OKG-0303), is a fixed-dose eye drop combining ranpirnase, an ocular decongestant and an antibacterial, in development for acute infectious conjunctivitis.

Ranpirnase has been dosed in more than 1,000 patients and shows significant selectivity indices against 23 viruses in independent testing.

Meet the Team

Milestones

Early 1970s
Kuslima Shogen, PhD and Tsunao Yoon, PhD carry out the extract discovery work with Rana pipiens embryos — the biological origin of ranpirnase.

1994
First published antiviral activity: Onconase inhibited HIV-1 replication by approximately 90–99.9% in infected H9 cells.

2015
Okogen, Inc. is founded. Ranpirnase first demonstrates activity against Ebola virus in infected cells and a mouse model.

2018
Okogen’s $10M Series A closes. First in-vitro and clinical evidence against HPV, including healing of anogenital warts in a Phase I study. The RUBY study is initiated.

2021
RUBY interim analysis reports safe, dose-responsive antiviral activity, but no improvement in signs and symptoms, which sets the design of the combination.

2022
Joshua Moriarty is appointed Chief Executive Officer.

2023
A corporate reorganization and re-focused strategy accompany the initiation of the program for OKG-0303.

2024
$3.3M in financing completes and introducing the AI evaluation tool for conjunctivitis.

2025
A regulatory application for the EMERALD study is submitted to CDSCO in India, and David Hollander is appointed Chief Medical Officer.

2026
CDSCO authorizes IND clearance and the EMERALD Phase 1/2 study commences.

Meet the Team

Management

Joshua Moriarty

Joshua H. Moriarty

CEO & Director

Joshua H. Moriarty

Chief Executive Officer

Joshua has more than 20 years of experience in ophthalmic product development, most recently serving as Executive Director at Ora, Inc., where he worked with emerging and mid-sized ophthalmic companies across the development lifecycle.

Read More

David A. Hollander, MD, MBA

Chief Medical Officer

David A. Hollander, MD, MBA

Chief Medical Officer

Hollander most recently also served as Chief Medical Officer and Global Therapeutics Commercial Lead at Revance Therapeutics, Inc, until its acquisition by Crown Laboratories in February 2025. Prior to Revance, Dr Hollander was the Chief Research and Development Officer of Aerie Pharmaceuticals, Inc. Dr. Hollander began his career in industry in 2006 at Allergan, Inc as a Medical Director of Ophthalmology where he also held a number of leadership roles including Vice President of Eye Care for U.S. Medical Affairs, Vice President and Head of Eye Care for Global Medical Affairs, as well as Therapeutic Area Head in Clinical Development for Anterior Segment and Consumer Eye Care. Dr. Hollander also serves as a Director for Kiora Pharmaceuticals (NASDAQ: KPRX).

During this time, Dr. Hollander continued to see patients and instruct residents and fellows in cataract surgery and corneal transplantation. Dr. Hollander previously also served as Chief Medical Officer of Ora, Inc, where he oversaw medical operations across pharmaceutical and device clinical development, preclinical studies, as well as research and development into new regulatory endpoints, most notably the development of novel mobility courses for evaluating treatments for inherited retinal diseases.

Dr. Hollander received his B.S. in chemistry with honors and distinction from Stanford University and earned his medical degree at the University of Pennsylvania School of Medicine. Dr. Hollander also obtained an M.B.A. in Health Care Management from the Wharton School at the University of Pennsylvania. Dr. Hollander completed his residency in ophthalmology at the University of California, San Francisco, and a Heed Fellowship in Cornea, External Disease and Refractive Surgery at the Jules Stein Eye Institute/University of California, Los Angeles.

Read More

Bradford A. Conlan

EXECUTIVE CHAIRMAN

Bradford A. Conlan

Executive Chairman

Mr. Conlan is a co-founder of Okogen, Inc. He is also a co-founder of Bayon Therapeutics (Acquired by Kiora Pharmaceuticals, NASDAQ: KPRX) and Bimini Health Tech where he has served as CEO and board member since 2013.

Mr. Conlan has over 18 years of experience in biotechnology, pharmaceutical and medical devices as an engineer, scientist, entrepreneur and investor. He received a B.S. in Biomedical and Industrial Engineering from the University of Iowa and an M.S. in Biomedical Engineering from the University of Southern California.

Read More

Independent Directors

Brian M Strem, PhD

Brian M Strem, PhD

Brian M Strem, PhD is a co-founder of Okogen Inc and current President & CEO of Kiora Pharmaceuticals (NASDAQ:KPRX). Previously, Brian worked at Sound Pharmaceuticals, Allergan and Shire, responsible for business development and corporate strategy in ophthalmology, otology and regenerative medicine. Brian began his career at Cytori Therapeutics with elevating roles within the commercial and R&D departments.

Brian received his BS in bioengineering from Cornell University and his PhD in biomedical engineering from UCLA.

Read More

Eric Daniels, MD, MBA

Eric Daniels, MD, MBA

Eric Daniels, MD, MBA is a Co-Founder of Okogen and is currently the Chief Development Officer at Plus Therapeutics (NASDAQ: PSTV). His previous experience includes Kiora Pharmaceuticals, Tensys Medical, Kerastem and Cytori Therapeutics. Eric has nearly 20 years of operating experience in biotechnology and medtech companies, including Tensys Medical, Kerastem, and Cytori Therapeutics, where he has held leadership roles within the commercial, medical and R&D organizations.

Eric holds a Masters of Business Administration from the Anderson School of Management at the University of California, Los Angeles. He received his Doctor of Medicine degree from the University of California, Los Angeles School of Medicine and his undergraduate degree in Molecular Biology from the University of California, Berkeley.

Read More

Quinton Oswald

Quinton Oswald

Quinton Oswald was the CEO of Notal Vision, a cloud based telemedicine company driven by AI tools. Prior to that, he served as CEO of Neurotech Pharmaceuticals and SARcode Bioscience, where he was instrumental in the clinical development of lifitegrast ophthalmic solution 5% (Xiidra™) for the treatment of dry eye disease (sold to Shire, PLC).

Previously, he served as the Vice President & Business Unit Head for Genentech’s Tissue Growth and Repair Business, where he also oversaw the  commercial launch of Lucentis® (ranibizumab) for the treatment of wet AMD. Prior to Genentech, Quinton led the North American Ophthalmology business for Novartis, which, in conjunction with QLT, Inc., pioneered Visudyne® (verteporfin), the first drug treatment for wet AMD.

Read More
Aiman

Aiman Shilad, MD, MBA

Aiman Shilad, MD, MBA

As a Director of Okogen Inc., Dr. Shilad, provides strategic oversight and guidance to support the company’s mission in ophthalmic therapeutics. With extensive experience in medical innovation and business development—including leadership roles at Johnson & Johnson, AbbVie, and Ethiconas a national advisor for new products, medications, and devices— he plays a key role in shaping corporate strategy, fostering strategic partnerships, and identifying growth opportunities. He remains in clinical practice as chair of Gyn Services, proctor for Robotic Minimally invasive surgery (Davinci Medical), professor at Hackensack Meridian School of Medicine.

Dr. Shilad holds a Masters of Business Administration from the Yale University School of Management He received his Doctor of Medicine degree from St George's University School of Medicine and his undergraduate degree in Biology from the St. Joseph's University. He completed his residency at Icahn School of Medicine/ Mt Sinai University.

Read More
Foltz

Joshua Foltz

Joshua Foltz

Mr. Foltz is an executive leader, who currently serves as CISO at NerdWallet, with deep expertise in FinTech, InsureTech, Artificial Intelligence, private equity and acquisition strategy. A seasoned operator, he has successfully overseen 15 mergers and acquisitions, excelling in business integration, technology integration and strategic growth.

Mr. Foltz has his Masters in Business Administration from Yale, has over 20 years of experience in technology and cyber security. At NerdWallet, he helped scale financial technology solutions, while at Insurity, he drove innovation in cloud-based insurance platforms. With a background in software development and product innovation, he thrives at the intersection of technology and finance.

Read More

Scientific & Medical Advisory Board

Francis Mah, MD

Jay Pepose, MD, PhD

John Sheppard, MD

Stephanie Watson, MD

Latest News & Press

View All News
Press Release

Okogen Acquires Ranpirnase Assets and Intellectual Property Portfolio

March 26, 2026
Read More
Press Release

Okogen Announces Regulatory Submission to CDSCO for EMERALD STUDY and Appointment of New Chief Medical Officer

April 2, 2025
Read More
News

Around the Globe Webinar Series: Latest Developments and Innovations at Okogen, Inc.

April 1, 2025
Read More
Main Menu